Skip to content

Vivace Therapeutics

5 viewers · 30d

Total raised

$17.5M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $17.5M
ROUNDS
1
INVESTORS
5
FOUNDED
N/A
HQ
San Mateo, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
5

AI overview

Updated

Vivace Therapeutics, Inc. is a pioneering biotechnology firm focused on creating innovative cancer treatments that specifically target the Hippo-YAP signaling pathway. The company aims to deliver solutions for cancer patients with limited options, particularly those suffering from challenging malignancies driven by pathway dysregulation.

What sets it apart

Vivace stands out by focusing on the Hippo pathway, which is often overlooked in cancer research, and has developed VT3989—a promising small molecule drug that has shown early success in clinical trials.

Funding history

1 round
EquityFeb 28, 2025
Form D
+$17.5M$17.5M total

Latest SEC filings

via EDGAR · CIK 0001630575
Form D · Feb 28, 2025View on EDGAR

Products

1 tracked

VT3989

Cancer Treatment

VT3989 is an innovative small molecule drug designed to inhibit TEAD autopalmitoylation within the Hippo signaling pathway. This mechanism aims to counteract the effects of pathway dysregulation that can lead to tumorigenesis, particularly in cancers like mesothelioma and other solid tumors characterized by NF2 mutations.

  • Targets the Hippo-YAP signaling pathway
  • Inhibits TEAD autopalmitoylation
  • Specifically developed for cancers with NF2 mutations
  • Promising early clinical trial results

Links

WebsiteSEC EDGAR filings